EpiBiologics
San Mateo, CA · Biotechnology · 43 employees
EpiBiologics is advancing bispecific antibodies that selectively degrade membrane and soluble proteins, including GPCRs. Our EpiTAC platform leverages a novel atlas of tissue-selective degrader receptors to drive deep and durable efficacy. The company was founded in 2022 based on pioneering work from Dr. Jim Wells at UCSF. Headquartered in the SF Bay Area, EpiBiologics is backed by leading healthc
Funding history
- Series SERIES B — $107.0M — Jan 2026
- Funding Round — $73.1M — Apr 2024
- Series series a — Undisclosed — Jul 2023
- Funding Round — $73.1M — Apr 2023
Recent signals
- Jan 08, 2026: Raised $107.0M in Series SERIES B
- Apr 25, 2024: Raised $73.1M
- Jul 20, 2023: Raised funding in Series series a
- Jul 20, 2023: EpiBiologics Appoints Ann Lee-Karlon as Chief Executive Officer and President, Extends Series A Financing to Over $70 Million
- Apr 28, 2023: Raised $73.1M
See plans & pricing → Track EpiBiologics’s funding, hiring, and signals — with verified contacts — on Fundz.